Heart transplant patients may get safer Anti-Rejection option
NCT ID NCT04477629
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether belatacept, an anti-rejection medication, is safe for adults who have just received a new heart. About 12 participants will receive the drug and be monitored for serious complications like rejection, infection, or organ failure. The goal is to find a better way to prevent the body from attacking the new heart.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University
ACTIVE_NOT_RECRUITINGNew York, New York, 10032, United States
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New study aims to spot heart transplant rejection without a biopsy
- Simple saltwater solution may shield kidneys after heart transplant
- Blood test may replace painful heart biopsies for transplant patients
- Heart transplant study aims to uncover hidden blood flow clues
- Heart transplant breakthrough: keeping donor hearts beating during transport could save more lives
- New MRI study peers inside Kids' hearts during exercise